Advertisement

Journal of Clinical Immunology

, Volume 38, Issue 3, pp 283–293 | Cite as

Complications Associated with Underweight Primary Immunodeficiency Patients: Prevalence and Associations Within the USIDNET Registry

  • Melanie A. Ruffner
  • USIDNET Body Weight Group
  • Kathleen E. Sullivan
Original Article
  • 127 Downloads

Abstract

Purpose

The point prevalence of underweight status and obesity in primary immunodeficiency disease (PID) is unknown, despite the described associations between PID and weight loss and failure to thrive. The goal of this study is to estimate the prevalence of underweight status and obesity in PID patients and to investigate the associations between abnormal body weight and complications of PID.

Methods

Using the US Immunodeficiency Network (USIDNET), we performed a retrospective analysis of 653 pediatric (age 2 to 20 years) and 514 adult (age > 20) patient records with information on patient body mass index (BMI). Prevalence of underweight and obese status in PID patients was compared to data from the National Health and Nutrition Examination Survey (NHANES).

Results

After separating BMI data by year of entry to the database, we demonstrated that both adult and pediatric patients with PID had significantly higher prevalence of underweight patients in multiple years of analysis. Further examination of underweight patients by PID diagnosis revealed that underweight status in adults with CVID was associated with granulomatous disease as well as earlier age of CVID diagnosis. In the pediatric CVID cohort, underweight status was significantly associated with lymphopenia. Examination of obesity in pediatric and adult PID patients compared to NHANES database revealed only a single year when obesity in PID patients was significantly less prevalent. In other 2-year time intervals from 2005 to 2014, the prevalence of obesity was unchanged in children and adults.

Conclusions

These results quantify the prevalence of underweight status in PID in a North American population and demonstrate that whether as a result of weight loss or poor weight gain, underweight status is more prevalent in the PID population than in the general US population. The prevalence of obesity in PID patients was similar to that seen in the general population. This highlights the need for continued education on the association of low weight and PID.

Clinical Trial Registration

NCT01953016

Keywords

Primary immunodeficiency common variable immunodeficiency failure to thrive obesity underweight National Health and Nutrition Examination Survey (NHANES) 

Abbreviations

PID

Primary immunodeficiency diseases

FTT

Failure to thrive

BMI

Body mass index

USIDNET

US Immunodeficiency Network

CDC

Center for Disease Control

CVID

Common variable immunodeficiency

SCID

Severe combined immunodeficiency

CGD

Chronic granulomatous disease

NHANES

National Health and Nutrition Examination Survey

Notes

Acknowledgments

We are grateful to primary immunodeficiency patients who shared their data for inclusion in USIDNET and to the members of USIDNET Body Weight Consortium who collected patient data for this cohort: Ramsay L. Fuleihan, Elizabeth Garabedian, Rebecca H. Buckley, Francisco A. Bonilla, Javeed Akhter, Daniel Suez, Jennifer Puck, Charolotte Cunningham-Rundles, Patricia Lugar, Niraj C. Patel, Elizabeth A. Secord, Elie Haddad, John Routes, Zuhair K. Ballas, Avni Joshi, Hans D. Ochs, Burcin Uygungil, Laurence Cheng, Vivian Hernandez-Trujillo, Leonard Calabrese, Karin Chen, Morna Dorsey, Mica Muskat, Mark Ballow, Mark R. Stein, Gary Kleiner, Warren Strober, Jim Fernandez, David Buchbinder, Heather Lehman, Sung-Yun Pai, Lisa Kobrynski, Luigi Notarangelo, Ralph Shapiro, Jason Caldwell, Kathleen Haines, Jason Raasch, Christine Seroogy, Andrea J. Apter, Melvin Berger, Patricia Costa Reis, Joseph DiBenedetto, Stewart Donn, Raif S. Geha, Christopher George, Gabriel E. Gonzalez, Richard J. Guillot, Kathleen E. Grundling, Caroline Horner, Robert Hostoffer, Peter Kim, Charles H. Kirkpatrick, Adina Knight, Roger H. Kobayashi, Peter Mustillo, Terry L. Overby, Marilyn Peitso, Robert Rabinowitz, Christopher Randolph, Robert L. Roberts, Phillip W. Smith, Bobo Tanner, James Verbsky, Martha White, Dowain Wright, Elizabeth M. Younger, and Grace Yu.

We would additionally like to thank Okan Elci for assistance with statistical analysis and Marla Goldsmith and Tara Caulder for help accessing USIDNET data.

Funding Information

MAR supported by USIDNET/Baxalta Grant and NIH T32-HD043021; KES is funded by The Wallace Chair of Pediatrics.

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Foundation TJM. 10 Warning signs [Internet]. [cited 2017 Jan 1]. Available from: http://www.info4pi.org/library/educational-materials/10-warning-signs
  2. 2.
    Lankisch P, Schiffner J, Ghosh S, Babor F, Borkhardt A, Laws HJ. The Duesseldorf warning signs for primary immunodeficiency: is it time to change the rules? J Clin Immunol. 2015;35:273–9.CrossRefPubMedGoogle Scholar
  3. 3.
    Subbarayan A, Colarusso G, Hughes MS, Gennery RA, Slatter M, Cant JA, et al. Clinical features that identify children with primary immunodeficiency diseases. Pediatrics. 2011;127:810–6.CrossRefPubMedGoogle Scholar
  4. 4.
    Reda SM, El-Ghoneimy DH, Afifi HM. Clinical predictors of primary immunodeficiency diseases in children. Allergy. Asthma. Immunol Res. 2013;5:88–95.Google Scholar
  5. 5.
    Guerrerio AL, Frischmeyer-Guerrerio PA, Lederman HM, Oliva-Hemker M. Recognizing gastrointestinal and hepatic manifestations of primary immunodeficiency diseases. J Pediatr Gastroenterol Nutr. 2010;51:548–55.CrossRefPubMedGoogle Scholar
  6. 6.
    Patel NC, Hertel PM, Estes MK, de la Morena M, Petru AM, Noroski LM, et al. Vaccine-acquired rotavirus in infants with severe combined immunodeficiency. N Engl J Med Massachusetts Medical Society. 2010;362:314–9.CrossRefGoogle Scholar
  7. 7.
    Barron MA, Makhija M, Hagen LE, Pencharz P, Grunebaum E, Roifman CM. Increased resting energy expenditure is associated with failure to thrive in infants with severe combined immunodeficiency. J Pediatr. 2011;159:628–32. e1 CrossRefPubMedGoogle Scholar
  8. 8.
    Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA American Medical Association. 2006;295:1549–55.CrossRefGoogle Scholar
  9. 9.
    Ogden CL, Troiano RP, Briefel RR, Kuczmarski RJ, Flegal KM, Johnson CL. Prevalence of overweight among preschool children in the United States, 1971 Through. 1994.Google Scholar
  10. 10.
    Troiano RP, Flegal KM, Kuczmarski RJ, Campbell SM, Johnson CL. Overweight prevalence and trends for children and adolescents. Arch Pediatr Adolesc Med American Medical Association. 1995;149:1085.CrossRefGoogle Scholar
  11. 11.
    Troiano RP, Flegal KM. Overweight children and adolescents: description, epidemiology, and demographics. Pediatrics. 1998;101.Google Scholar
  12. 12.
    Jahn J, Spielau M, Brandsch C, Stangl GI, Delank KS, Bähr I, et al. Decreased NK cell functions in obesity can be reactivated by fat mass reduction. Obesity. 2015;23:2233–41.CrossRefPubMedGoogle Scholar
  13. 13.
    Laue T, Wrann CD, Hoffmann-Castendiek B, Pietsch D, Hübner L, Kielstein H. Altered NK cell function in obese healthy humans. BMC Obes. 2015;2:1.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Nieman DC, Nehlsen-Cannarella SI, Henson DA, Butterworth DE, Fagoaga OR, Warren BJ, et al. Immune response to obesity and moderate weight loss. Int J Obes Relat Metab Disord. 1996;20:353–60.PubMedGoogle Scholar
  15. 15.
    Tanaka S, Inoue S, Isoda F, Waseda M, Ishihara M, Yamakawa T, et al. Impaired immunity in obesity: suppressed but reversible lymphocyte responsiveness. Int J Obes Relat Metab Disord. 1993;17:631–6.PubMedGoogle Scholar
  16. 16.
    Han SN, Jeon KJ, Kim MS, Kim H-K, Lee AJ. Obesity with a body mass index under 30 does not significantly impair the immune response in young adults. Nutr Res. 2011;31:362–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011;11:85–97.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Lee B-C, Lee J. Cellular and molecular players in adipose tissue inflammation in the development of obesity-induced insulin resistance ☆. 2014Google Scholar
  19. 19.
    Sullivan KE, Puck JM, Notarangelo LD, Fuleihan R, Caulder T, Wang C, et al. USIDNET: a strategy to build a community of clinical immunologists. J Clin Immunol. 2014;34:428–35.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Centers for Disease Control and Prevention NC for HS. Data Table of BMI-for-age Charts. August 24, 2001. p. https://www.cdc.gov/growthcharts/html_charts/bmiag.
  21. 21.
    Kuczmarski RJ, Ogden CL, Guo SS, Grummer-Strawn LM, Flegal KM, Mei Z, et al. CDC growth charts for the United States: methods and development. Vital Health Stat. 2000;11(2002):1–190.Google Scholar
  22. 22.
    Garrow JS, Webster J. Quetelet’s index (W/H2) as a measure of fatness. Int J Obes. 1985;9:147–53.PubMedGoogle Scholar
  23. 23.
    Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA. 2012;307:491–7.CrossRefPubMedGoogle Scholar
  24. 24.
    Ogden C, Carroll M, Lawman H, Fryar C, Kruszon-Moran D, Kit B, et al. Trends in obesity prevalence among children and adolescents in the united states, 1988–1994 through 2013–2014. JAMA Am Med Assoc; 2016; 2292–9.Google Scholar
  25. 25.
    Fryar CD, Carroll MD, Ogden CL. Prevalence of underweight among adults aged 20 and over: United States, 1960–1962 through 2013–2014 [Internet]. 2016. p 2. Available from: https://www.cdc.gov/nchs/data/hestat/underweight_adult_13_14/underweight_adult_13_14.pdf.
  26. 26.
    Fryar CD, Carroll MD, Ogden CL. Prevalence of underweight among children and adolescents aged 2–19 years: United States, 1963–1965 through 2013–2014 [Internet]. 2016. Available from: https://www.cdc.gov/nchs/data/hestat/underweight_child_13_14/underweight_child_13_14.pdf.
  27. 27.
    Johnson CL, Dohrmann SM, Burt VL, Mohadjer LK. National Health and nutrition examination survey: sample design, 2011–2014. Vital Heal Stat. 2014;2:1–33.Google Scholar
  28. 28.
    Curtin LR, Mohadjer LK, Dohrmann SM. National Health and Nutrition Examination Survey : sample design, 2007–2010. Vital Heal Stat. 2010;160:1–32.Google Scholar
  29. 29.
    Curtin LR, Mohadjer LK, Dohrmann SM, Montaquila JM, Kruszan-Moran D, Mirel LB, et al. The National Health and nutrition examination survey: sample design, 1999-2006. Vital Health Stat. 2012;2:1–39.Google Scholar
  30. 30.
    National Health and Nutrition Examination Survey. 2013–2014 data documentation, codebook, and frequencies, demographic variables and sample weights [Internet]. Oct. 2015. Available from: https://wwwn.cdc.gov/Nchs/Nhanes/2013-2014/DEMO_H.htm.
  31. 31.
    Flegal KM, Kruszon-Moran D, Carroll MD, Fryar CD, Ogden CL. Trends in obesity among adults in the United States, 2005 to 2014. JAMA. 2016;315:2284–91.CrossRefPubMedGoogle Scholar
  32. 32.
    Al-Herz W, Moussa MAA. Survival and predictors of death among primary immunodeficient patients: a registry-based study. J Clin Immunol. 2012;32:467–73.CrossRefPubMedGoogle Scholar
  33. 33.
    Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol. 1999;92:34–48.CrossRefPubMedGoogle Scholar
  34. 34.
    Boileau J, Mouillot G, Gérard L, Carmagnat M, Rabian C, Oksenhendler E, et al. Autoimmunity in common variable immunodeficiency: correlation with lymphocyte phenotype in the French DEFI study. J Autoimmun. 2011;36:25–32.CrossRefPubMedGoogle Scholar
  35. 35.
    Wong GK, Huissoon AP. T-cell abnormalities in common variable immunodeficiency: the hidden defect. J Clin Pathol. 2016;69:672–6.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Nieman DC, Henson D a, Nehlsen-Cannarella SL, Ekkens M, Utter a C, Butterworth DE, et al. Influence of obesity on immune function. J Am Diet Assoc. 1999; 294–9.Google Scholar
  37. 37.
    Weber DJ, Rutala WA, Samsa GP, Santimaw JE, Lemon SM. Obesity as a predictor of poor antibody response to hepatitis B plasma vaccine. JAMA American Medical Association. 1985;254:3187–9.CrossRefGoogle Scholar
  38. 38.
    Sheridan PA, Paich HA, Handy J, Karlsson EA, Hudgens MG, Sammon AB, et al. Obesity is associated with impaired immune response to influenza vaccination in humans. Int J Obes Nature Publishing Group. 2012;36:1072–7.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Melanie A. Ruffner
    • 1
    • 2
  • USIDNET Body Weight Group
  • Kathleen E. Sullivan
    • 1
    • 2
  1. 1.Division of Allergy and ImmunologyChildren’s Hospital of PhiladelphiaPhiladelphiaUSA
  2. 2.Department of PediatricsPerelman School of Medicine at University of PennsylvaniaPhiladelphiaUSA

Personalised recommendations